{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:22:17Z","timestamp":1771233737182,"version":"3.50.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer. We examined the skin lesions on their entire body by polarized and nonpolarized dermoscopy. A total of 21 suspicious lesions in the first group and 17 in the second one were removed and histologically analyzed. Twelve (9.4%) cancerous or precancerous lesions were found in the first group: seven (5.5%) basal cell carcinoma (BCC) and five actinic keratosis. The mean time to cancer onset was identified as 22 months after the start of four therapy, with an SD of 18 months, suggesting an earlier onset with respect to the start of therapy in our population. On univariate analysis, age (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.001) and age of psoriasis onset (0.009) were statistically significant. Nine of 17 were skin cancers in the second group. Our study provided real-life evidence of the percentage of patients with skin cancers during therapy with anti-IL mAbs, demonstrating a good safety profile of the investigated drugs.<\/jats:p>","DOI":"10.1097\/cej.0000000000000948","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:00:34Z","timestamp":1736424034000},"page":"571-580","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study"],"prefix":"10.1097","volume":"34","author":[{"given":"Flavia","family":"Manzo Margiotta","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pisa"},{"name":"Interdisciplinary Center of Health Science, Sant'Anna School of Advanced Studies of Pisa, Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Fidanzi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"},{"name":"Melanoma and Skin Cancer Unit, AVNO Tuscany, Livorno"},{"name":"Massa-Carrara Hospitals, Massa Carrara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Pardossi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"},{"name":"Interdisciplinary Center of Health Science, Sant'Anna School of Advanced Studies of Pisa, Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"},{"name":"Interdisciplinary Center of Health Science, Sant'Anna School of Advanced Studies of Pisa, Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammarco","family":"Granieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Salvia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Bevilacqua","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[{"name":"Statistical Support to Clinical Trials Department, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Panduri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Bagnoni","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Cancer Unit, AVNO Tuscany, Livorno"},{"name":"Massa-Carrara Hospitals, Massa Carrara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Janowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"R1-20250930","first-page":"49","article-title":"Sunlight and skin cancer.","volume":"1","author":"Ananthaswamy","year":"2001","journal-title":"J Biomed Biotechnol"},{"key":"R2-20250930","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1011-1344(01)00198-1","article-title":"The epidemiology of UV induced skin cancer.","volume":"63","author":"Armstrong","year":"2001","journal-title":"J Photochem Photobiol B"},{"key":"R3-20250930","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure.","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R4-20250930","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00383-018-4388-0","article-title":"Melanoma in children, adolescents and young adults: anatomo-clinical features and prognostic study on 426 cases.","volume":"35","author":"Bagnoni","year":"2019","journal-title":"Pediatr Surg Int"},{"key":"R5-20250930","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis.","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R6-20250930","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R7-20250930","first-page":"1109","article-title":"Psoriasis therapy and skin cancer: a review.","volume":"11","author":"Butr\u00f3n-Bris","year":"2021","journal-title":"Life (Basel)"},{"key":"R8-20250930","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2023.2247972","article-title":"The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries.","volume":"23","author":"Calamia","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R9-20250930","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis.","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"R10-20250930","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network.","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R11-20250930","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/ijms19010179","article-title":"Scanning the immunopathogenesis of psoriasis.","volume":"19","author":"Chiricozzi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R12-20250930","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.intimp.2018.06.020","article-title":"Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials[.","volume":"62","author":"Cui","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"R13-20250930","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00403-023-02796-y","article-title":"Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population.","volume":"316","author":"Deike","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"R14-20250930","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1684\/ejd.2017.3126","article-title":"Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics.","volume":"27","author":"Fargnoli","year":"2017","journal-title":"Eur J Dermatol"},{"key":"R15-20250930","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"R16-20250930","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0000000000000778","article-title":"Risk factors in pediatric melanoma: a retrospective study of 39 cases.","volume":"31","author":"Fidanzi","year":"2021","journal-title":"Melanoma Res"},{"key":"R17-20250930","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/CEJ.0000000000000747","article-title":"Epidemiology of melanoma: the importance of correctly reporting to the cancer registries.","volume":"31","author":"Fidanzi","year":"2022","journal-title":"Eur J Cancer Prev"},{"key":"R18-20250930","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CEJ.0000000000000774","article-title":"Epidemiology of Merkel cell carcinoma in Tuscany (Italy), 2006-2021.","volume":"32","author":"Fidanzi","year":"2023","journal-title":"Eur J Cancer Prev"},{"key":"R19-20250930","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ypmed.2010.11.012","article-title":"Sun exposure and children: what do they know? An observational study in an Italian school.","volume":"52","author":"de Giorgi","year":"2011","journal-title":"Prev Med"},{"key":"R20-20250930","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jdv.16966","article-title":"Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.","volume":"35","author":"Golbari","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R21-20250930","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.soncn.2013.06.002","article-title":"Skin cancer: an overview of epidemiology and risk factors.","volume":"29","author":"Gordon","year":"2013","journal-title":"Semin Oncol Nurs"},{"key":"R22-20250930","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R23-20250930","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"R24-20250930","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-020-00512-4","article-title":"Malignancy rates in brodalumab clinical studies for psoriasis.","volume":"21","author":"Gottlieb","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R25-20250930","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"R26-20250930","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.drup.2023.100937","article-title":"Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance.","volume":"67","author":"Guo","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R27-20250930","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2133.2011.10430.x","article-title":"Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin.","volume":"165","author":"Heier","year":"2011","journal-title":"Br J Dermatol"},{"key":"R28-20250930","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) [published correction appears in J Rheumatol. 2018 Nov;45(11):1608].","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"R29-20250930","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.","volume":"72","author":"Kimball","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R30-20250930","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids.","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R31-20250930","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors.","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R32-20250930","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R33-20250930","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"R34-20250930","doi-asserted-by":"crossref","first-page":"934396","DOI":"10.3389\/fphar.2022.934396","article-title":"Non-coding RNAs in skin cancers: biological roles and molecular mechanisms.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R35-20250930","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R36-20250930","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease.","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"R37-20250930","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry.","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R38-20250930","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R39-20250930","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology.","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"R40-20250930","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: treatment and monitoring recommendations.","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R41-20250930","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"Suppl 3","key":"R42-20250930","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies.","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R43-20250930","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"R44-20250930","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks [published correction appears in Br J Dermatol. 2022 Jul;187(1):131-132].","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"R45-20250930","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease.","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"R46-20250930","first-page":"1059","article-title":"Non-melanoma skin cancer risk among patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"18","author":"deShazo","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R48-20250930","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2340\/00015555-0360","article-title":"Long-term follow-up of cancer risk in patients treated with short-term cyclosporine.","volume":"88","author":"V\u00e4kev\u00e4","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"R49-20250930","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.7150\/jca.37015","article-title":"Risk of non-melanoma skin cancer in patients with psoriasis: an updated evidence from systematic review with meta-analysis.","volume":"11","author":"Wang","year":"2020","journal-title":"J Cancer"},{"key":"R50-20250930","doi-asserted-by":"crossref","first-page":"216397","DOI":"10.1016\/j.canlet.2023.216397","article-title":"Nano-drug delivery system targeting tumor microenvironment: a prospective strategy for melanoma treatment.","volume":"574","author":"Xu","year":"2023","journal-title":"Cancer Lett"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:08Z","timestamp":1759237448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000948","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}